Rhamy Zeid
Chief Scientific Officer Nexo Therapeutics
Rhamy Zeid is Chief Scientific Officer and a founder of Nexo Therapeutics, Inc. Prior to joining Nexo, Dr. Zeid served as Head of Discovery Biology at Nested Therapeutics. Previously, he was Head of Target Biology at C4 Therapeutics. Dr. Zeid received his Ph.D. in Biological and Biomedical Sciences from Harvard Medical School and holds a B.S. in biology from Northeastern University.
Seminars
Wednesday 21st October 2026
Fireside Chat: Interpreting Preclinical Safety Data to Support First in Human & Early Clinical Decisions for Covalent Drugs
4:30 pm
- How are different organizations assessing covalent safety risk prior to first in human studies, and how are these assessments informing starting dose and escalation strategy?
- How reliably do preclinical toxicity and target engagement signals translate across species for covalent drugs, and where do current models consistently fail to predict clinical outcomes?
- What practical criteria are teams using today to progress covalent candidates into the clinic in the absence of definitive, predictive safety models?
